Tactics II Ventures

Tactics II Ventures is a private venture capital and investment firm specializing in the life sciences, biotechnology, and longevity sectors. Co-founded by prominent investors Jim Mellon and Dr. Greg Bailey, the firm is known for identifying and seeding high-growth healthcare companies at their earliest stages. Tactics II Ventures played a pivotal role as a founding investor in Biohaven Pharmaceuticals, which developed the blockbuster migraine drug Nurtec ODT before being acquired by Pfizer. The firm also holds strategic positions in other innovative entities such as Juvenescence and Portage Biotech. By leveraging the deep industry expertise of its principals, Tactics II Ventures focuses on advancing transformative medical technologies and therapeutic platforms. It operates primarily as a private investment vehicle for its founders to manage their biotech-related interests and venture formations.